Auristone is pleased to announce a strategic partnership with South Korea’s leading genomic company, IMBdx, to offer a bundled solution combining genomic and epigenomic profiling for enhanced clinical insights.

Auristone’s EPI-CALL™ report will be bundled with IMBdx’s CancerDetect™ and CancerProfiler™ genomic reports. CancerDetect™ is a hybrid-capture NGS-based liquid biopsy test designed for Minimal Residual Disease (MRD) detection and surveillance in solid tumour patients, while CancerProfiler™ provides comprehensive tissue-based genomic profiling aimed at understanding tumour molecular biology.

EPI-CALL™ complements these offerings with an epigenomic perspective—delivering clinically actionable insights based on gene regulation and chromatin state. A key feature, the Predict-IO Score, predicts likelihood of response to immunotherapy independent of conventional biomarkers such as TMB, MSI, and PD-L1.

This collaboration aims to provide a more comprehensive toolset for clinical researchers conducting trials and exploring precision oncology strategies. The partnership will span an initial 2–3 years, with joint efforts focused on supporting clinical research and expanding access to integrated biomarker solutions in Korea.